



3rd Quarter Financial Results for FYE/Mar. 2007

Results Overview and Topics

Terumo Corporation

Sales and profits continuing to enjoy double-digit growth

(Unit: billion yen)

	3Q FYE/Mar. 2006	3Q FYE/Mar. 2007	Rate of change
Net Sales	183.6	205.1	11.7%
Gross Profit (%)	100.1 (54.5%)	113.2 (55.2%)	13.1%
SGA Expenses (%)	61.4 (33.4%)	68.0 (33.2%)	10.7%
Operating Income (%)	38.7 (21.1%)	45.2 (22.0%)	16.9%
Ordinary Income (%)	39.3 (21.4%)	46.3 (22.5%)	17.7%
Net Income (%)	25.0 (13.6%)	29.5 (14.4%)	18.0%

Average
exchange rate

US\$
EUR


112 yen
137 yen

116 yen
148 yen

3.6% yen depreciation
8.1% yen depreciation

Net Sales (by product group)

(Unit: billion yen)



Consolidated total: 11.7%


- CV and vascular grafts
(Growth rate: 18.3%)
- Interventional products
(Growth rate: 27.0%)
- Home health care products
(Growth rate: 2.6%)
- General hospital products
(Growth rate: 6.1%)

3Q FYE/Mar. 2006

3Q FYE/Mar. 2007

Net Sales (by Region)

(Unit: billion yen)



Overseas sales ratio (%)

39%

44%

Consolidated Net Sales


	11.7%	(9.5%)
Asia&Others	16.8%	(11.1%)
Americas	33.4%	(29.8%)
Europe	3.3%	(15.2%)
Overseas	26.0%	(20.2%)
Japan	2.7%	

Excluding impact of foreign exchange

Gross Profit Margin: 55.2% +0.7pt compared to previous year


Positive factors : +1.6pt

Negative factors : ▲0.9pt



Details of SGA Expenses

(Unit: billion yen)



SGA Expenses rate
 33.4% 33.2%

▲0.2pt

Expecting to Achieve the Forecast for Full Fiscal Year

(Unit: billion yen)

	FYE/Mar. 2006	FYE/Mar. 2007 (forecast)	Increase rate
Net Sales	247.0	273.0	11%
Operating Income (%)	48.3 (19.5%)	57.5 (21.1%)	19%
Ordinary Income (%)	48.9 (19.8%)	57.5 (21.1%)	18%
Net Income (%)	32.5 (13.1%)	37.0 (13.6%)	14%

Exchange rate
for the year

US\$ 113 yen
EUR 138 yen

US\$ 116 yen
EUR 148 yen



Topics


Latest clinical trial data

(as of January 25, 2007)

Mean age (Average)	54.5
Mean duration of support (days)	165
No. of patients supported > 6 months (> 12 months)	11 (4)
Overall survival (%)	76
Mean days of hospitalisation (days)	45

Differences identified in long-term survival

Comparison by the Kaplan-Meier Survival Analysis




- **Europe: CE Mark expected in the 4th quarter this fiscal year**
- **U.S. : Application for clinical trial planned in the next fiscal year**
- **Japan : Preparation in progress for application for clinical trial**




Drug-eluting stent "Nobori"

- **Europe: CE Mark expected in 4th quarter this fiscal year**
- **Japan : Preparation in progress, application for clinical trial**
- **Implant of 360 cases completed**



Sales in Japan now in recovery



Pharmaceuticals drive the business in Japan

➤ I.V. solution

- Standardization and streamlining of products in progress, expanding sales
- Good sales of new product with superb risk management functions, "Amigrand"



"Amigrand"

➤ Pre-filled syringes

- Minofit sales gradually increasing
- Good sales of contrast media continuing



"Minofit"

Syringe for liver disease and allergies


Sales of diabetes care products continue to grow

- **Device for glucose monitoring, "Medisafe Mini"**
 - 22% share in Japan
 - Focusing on safety and convenience



"Medisafe Mini"

- **Insulin needles, "NanoPass"**
 - Domestic sales gradually increasing
 - Production capability to be increased in future



Reduce pain needle

"NanoPass"

Joint Venture with Olympus

- Terumo's collagen business joining forces with Olympus' biomaterial and regenerative medicine business


"Olympus Terumo Biomaterial Corp."

(Established on April 1, 2007)

- **Development of new composite artificial bone substitute material**

- Application to treatment of bone diseases (fractures and bone tumors)
- Creating new markets for minimally invasive therapies by developing patient-friendly biomaterials

- **Securing a foothold for the entering orthopedics market**



New composite bone substitute material image



IR Contact

TERUMO Corporation

Corporate Communication (IR) Dept.

E-mail: Kazuya_Haraguchi@terumo.co.jp

This document contains forward-looking statements that reflect management's current views with respect to certain future events and financial performance. Actual results may differ materially from those projected or implied in the forward-looking statements and from historical trends. Furthermore, certain forward-looking statements are based upon assumptions of future events that may not prove to be accurate. Factors that could cause actual results to differ materially from those projected or implied in any forward-looking statements include, but are not limited to, changes in overall economic conditions, fluctuations of foreign exchange rates, and intensifying price competition in the markets for our products.